In view of this, the status of the <i>TP53</i> gene, which is mutated or deleted in 20-30% of the cases, has emerged as an important prognostic factor for DLBCL patients, setting itself apart from other predictors. The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.